Healthspan becomes a bigger part of the healthy ageing debate

Genflow Biosciences Plc

Living longer is only part of the ageing story. Increasingly, the focus is moving towards how many of those years are spent in good health. Lifespan refers to the total number of years a person lives. Healthspan refers to the years spent in relatively good physical and mental health, with fewer serious limitations caused by disease, pain or loss of independence.

Longer life does not always mean healthier life. People may live for many years while managing chronic conditions that affect mobility, independence and overall quality of life. As a result, healthy ageing is becoming less about extending life alone and more about extending the period of life spent in good health.

This shift has wider relevance as ageing populations increase demand for healthcare, prevention, monitoring and long-term support. It also places more attention on the factors that can influence health over time.

Genetics remains part of the picture, but lifestyle and environment can also play an important role. Regular physical activity, a balanced diet, good sleep, avoiding tobacco and maintaining social connections can all support healthier ageing. Preventive healthcare, including routine checks and appropriate screening, can also help identify potential problems earlier.

Managing common health risks is another important part of maintaining healthspan. Blood pressure, cholesterol, blood sugar and body weight can influence the risk of developing conditions that become more common with age. Addressing these areas earlier may help reduce the impact of disease later in life.

Physical strength and mobility are particularly important. Maintaining muscle, balance and cardiovascular fitness can support independence and reduce the likelihood that everyday activities become more difficult with age.

Mental and social wellbeing also contribute to healthy ageing. Staying connected with other people, remaining mentally active and managing stress can support overall health alongside more traditional medical measures.

Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Genflow Biosciences secures Japanese patent and expands animal health partnerships

Genflow Biosciences has secured Japanese patent allowance for its SIRT6 gene therapy, with all 16 claims approved, and signed additional confidentiality agreements with animal health companies. Its regional grant application is under review, with no impact on financial guidance expected.

Genflow Biosciences: SLAB-VET Results Put SIRT6 Partnering and Human Therapies in Focus (video)

Genflow Biosciences’ latest SLAB-VET-001 results are sharpening the commercial case for its SIRT6c platform. CEO Dr Eric Leire discusses the signals seen in naturally aged dogs, why pDNA is leading the veterinary programme, growing interest from animal health companies and how progress could feed into Genflow’s human sarcopenia strategy.

Genflow Biosciences examines the role of genes in ageing

Genflow Biosciences is investigating a SIRT6 gene variant associated with longevity as part of its research into therapies targeting biological ageing.

Genflow reports SIRT6 gene therapy results in aged dogs

Genflow reports reduced epigenetic age in dogs treated with its SIRT6c gene therapy, with pDNA selected as the lead delivery method for its veterinary programme.

Genflow completes SLAB trial as human and animal health programmes advance

Genflow Biosciences completed its SLAB canine healthspan and sarcopenia trial in H1 2026, with the company reporting safety and tolerability data for GF-1004. The group also advanced its glaucoma, MASH, Mitosir and Exofastrack programmes while ending the period with £632,553 in cash.

Age-related disease keeps biotechnology research in focus

Age-related conditions such as glaucoma and sarcopenia continue to support interest in biotechnology research focused on the biology of ageing.

Search